A cquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v trials, combined dabrafenib and trametinib was associated with significant improvements in outcomes compared with dabrafenib or vemurafenib monotherapy, in patients with BRAF-mutant metastatic melanoma. The combination of vemurafenib and cobimetinib has also been investigated. In the phase III CoBRIM study in patients with unresectable stage III-IV BRAF-mutant melanoma, treatment with vemurafenib and cobimetinib resulted in significantly longer progression-free survival and overall survival (OS) compared with vemurafenib alone. One-year OS was 74.5% in the vemurafenib and cobimetinib group and 63.8% in the vemurafenib group, while 2-year OS rates were 48.3% and 38.0%, respectively. The combination was also well tolerated, with a lower incidence of cutaneous squamous-cell carcinoma and keratoacanthoma compared with monotherapy. Dual inhibition of both MEK and BRAF appears to provide a more potent and durable anti-tumour effect than BRAF monotherapy, helping to prevent acquired resistance as well as decreasing adverse events related to BRAF inhibitor-induced activation of the MAPK-pathway. Combined BRAF and MEK inhibition is the standard of care in patients with advanced BRAF-mutant melanoma.
Review Melanoma
BRAF inhibitors typically result in a rapid response to treatment, with an early reduction in symptom burden and improved performance status. This appears to be especially marked in patients with the most severe clinical condition (the so-called "Lazarus Effect") and is mediated through a fast metabolic disease shutdown and a slower decrease in the size of metastatic lesions.
BRAF inhibitors are generally well tolerated with the most common toxicities being rash, fatigue and joint pain. Vemurafenib is associated with an increased frequency of photosensitivity than dabrafenib although pyrexia is less frequent. Increased cutaneous squamous-cell carcinoma (SCC) and keratoacanthoma (KA) has been observed with both vemurafenib (26% of patients) and dabrafenib (14% of patients), usually within the first 2 months of treatment. 6, 7 This toxicity appears to be secondary to the paradoxical activation of the MAPK pathway in keratinocytes together with activation of RAS mutation mediated signaling. 8, 9 
MEK inhibitors
The first MEK inhibitor to be approved for the treatment of advanced BRAF V600 mutant melanoma was trametinib in 2014. In a phase II clinical trial, trametinib showed significant clinical activity in BRAF inhibitor-naïve metastatic melanoma patients previously treated with chemotherapy and/or immunotherapy (median PFS: 4.0 months; 2% complete response, 23% partial response). 10 However, minimal clinical activity was observed when given as sequential therapy in patients previously treated with a BRAF inhibitor (median PFS: 1.8 months; no confirmed responses), suggesting that BRAF inhibitor resistance mechanisms also confer resistance to MEK inhibitors. In the randomised phase III METRIC trial, 322 previously treated (immuno-or chemotherapy) BRAF inhibitor-naïve patients with advanced BRAF-mutant melanoma were randomised to trametinib 2 mg once daily or chemotherapy with dacarbazine or paclitaxel. 11 Trametinib was associated with improvements in response rate (22% versus 8%), median PFS (4.8 versus 1.5 months; p<0.001) and 6-month OS (81% versus 67%; HR 0.54, p=0.01). Hypertension, rash and fatigue were the most commonly reported grade 3 adverse effects and were manageable by dose interruption and dose reduction. Although approved as monotherapy for the treatment of BRAF V600 mutant metastatic melanoma, trametinib is not often used as such because BRAF inhibitor monotherapy is perceived to have greater efficacy.
BRAF inhibitor and MEK inhibitor combination therapy
The most common cause of BRAF inhibitor monotherapy treatment failure is acquired resistance, with most patients experiencing disease progression with a median PFS of 6-8 months. Reactivation of the MAPK pathway is thought to be the main cause of acquired resistance, 12, 13 although MAPK-independent signalling through receptor tyrosine kinases has also been linked to the development of resistance. 14, 15 In preclinical studies, addition of a MEK inhibitor to a BRAF inhibitor decreased tumour growth, delayed the development of resistance and reduced the occurrence of skin lesions in metastatic melanoma models. 16 As such, there has been considerable focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy ( Table 1) .
Dabrafenib plus trametinib
In a randomised open-label study of 162 patients with BRAF V600-mutant metastatic melanoma, median PFS in patients receiving dabrafenib plus trametinib in combination was 9.4 months compared with 5.8 months in patients treated with dabrafenib monotherapy (HR for progression or death, 0.39; 95% CI, 0.25-0.62; p<0.001). 17 Combination treatment was well tolerated with infrequent dose-limiting toxicities. In the subsequent phase III COMBI-d trial involving 423 previously untreated patients with stage IIIC-IV BRAF-mutant melanoma, median PFS was 9.3 months in patients randomised to dabrafenib plus trametinib versus 8.8 months 
CI = confidence interval; HR = hazard ratio; OS = overall survival
in patients randomised to dabrafenib plus placebo (HR for progression or death 0.75; 95% CI, 0.57-0.99; p=0.03). 18 The overall response rate (ORR) was also significantly improved with combination treatment (67% versus 51%; p=0.002). Adverse events were generally similar in the two groups, although the combined therapy group had a lower rate of cutaneous SCC (2% versus 9%) and a higher rate of pyrexia (51% versus 28%) which was more often severe. In an update of these data, 19 One-, 2-and 3-year OS rates were 74%, 51% and 44% in the combination group as compared with 68%, 42% and 32% in the dabrafenib group. The combination of dabrafenib and trametinib also provided significantly better health-related quality-of-life versus dabrafenib monotherapy. 20 The combination of dabrafenib plus trametinib was also assessed in the COMBI-v trial, in which it was compared with vemurafenib alone as firstline treatment in 704 BRAF-mutant patients with metastatic melanoma. Median OS was 26.1 months with combination therapy versus 17.8 months with vemurafenib alone. The survival benefit with dabrafenib plus trametinib was maintained at 2 and 3 years with, respectively, 53% and 45% of patients receiving the combination treatment still alive compared with 39% and 31% of patients receiving vemurafenib alone. Significantly improved PFS was also maintained (12.6 months with dabrafenib plus trametinib versus 7.3 months with vemurafenib). Two-and 3-year PFS in the dabrafenib plus trametinib group was 30% and 24% compared with 16% and 10% in the vemurafenib group. 22 
Vemurafenib and cobimetinib
The combination of vemurafenib with cobimetinib, a potent, selective MEK1/2 inhibitor, has also been a focus of investigation. In the phase Ib BRIM-7 trial, 129 patients who had either recently progressed on vemurafenib or had never received a BRAF inhibitor were treated with combined vemurafenib and cobimetinib in a variety of dosing regimens (vemurafenib 720 mg or 960 mg twice a day continuously and cobimetinib 60 mg, 80 mg, or 100 mg once a day for either 14 days on and 14 days off, 21 days on and 7 days off, or continuously). 23 In BRAF inhibitor-naïve patients, the ORR was 87% and PFS was 13.7 months, although BRAF inhibitor pre-treated patients had a shorter PFS (2.8 months). Median PFS was 13.8 months (95% CI 10.1-20.6) and median OS was 28.5 months (23.3-34.6) with a 2-year OS rate of 61% (95% CI 47.8-74.4). 24 The combination of vemurafenib and cobimetinib was generally well tolerated. The most frequent adverse events were similar to those with single agent monotherapy rash, (diarrhoea, photosensitivity and aspartate aminotransferase/alanine aminotransferase [ALT]) elevation, while there was a lower incidence of cutaneous SCC and KA.
Vemurafenib and cobimetinib combination therapy was further assessed in the CoBRIM trial, a multicentre, phase III study in which 495 patients with unresectable stage IIIC-IV BRAF-mutant melanoma were randomised to receive cobimetinib 60 mg once daily with a 21 days on, 7 days off schedule plus vemurafenib 960 mg twice daily (n=247) or vemurafenib plus placebo (n=248). 25 Treatment was continued until the occurrence of disease progression, unmanageable toxicity or withdrawal of consent.
Investigator-assessed PFS was the study primary endpoint and OS, ORR and duration of response (DOR) were secondary end points. Figure 1) . One-year OS was 74.5% (95% CI 68. 9-80.2) in the vemurafenib and cobimetinib group and 63.8% (57.6-70.0) in the vemurafenib group while 2-year OS was 48.3% (41.4-55.2) and 38.0% (31.3-44.7), respectively. ORR was similar to those at the primary analysis, although more patients achieved a complete response (16% versus 10% in the vemurafenib and cobimetinib group and 11% versus 4% in the vemurafenib group), indicating that some patients had a better response when treatment was maintained.
Several tumour molecular markers were analysed at baseline to assess the possible effects of proliferative state (Ki67), MAPK activation (pERK) and pS6 (PI3K-MAPK downstream effector) on survival outcomes. Tolerability was similar in the primary analysis and longer-term follow-up.
Most of the side effects occurring with combination therapy were mild to moderate in severity (grade 1-2), although there was an increased incidence of grade ≥3 treatment-related adverse events compared with vemurafenib monotherapy (60% versus 52%). 26 The most frequent grade 3-4 adverse events that had a higher occurrence in the vemurafenib and cobimetinib group were increases in γ-glutamyl transferase, blood creatine phosphokinase (CPK) and ALT. However, direct comparisons between trials are not feasible due to differences in patient characteristics and study designs e.g. the CoBRIM study did not allow crossover of patients from the vemurafenib group to the combination group with disease progression. In addition, PFS and ORR in the vemurafenib monotherapy arm were in line with results in previous randomised trials of vemurafenib monotherapy. 3, 7 The CoBRIM trial enrolled a higher proportion of patients with elevated baseline LDH levels (around 50%) compared with previous BRAF-MEK inhibitor studies. These patients have been shown to have a poorer prognosis in several trials. 3, 21 In the COMBI-v and COMBI-d trials, around 70% of patients had normal LDH levels, which might explain why patients receiving monotherapy in these studies had improved outcomes compared with previous studies (PFS of 7.6 months for vemurafenib and 8.8 months for dabrafenib compared with 6 months in initial phase II-III monotherapy trials). In the CoBRIM study, patients with raised LDH had shorter median survival than those with normal LDH levels in both treatment arms. These patients are often considered for treatment options other than BRAF or MEK-targeted therapies; however, they could benefit from long-term therapy with cobimetinib and vemurafenib.
In addition to targeted therapies, recent advances in the treatment and prognosis of advanced melanoma also include immune checkpoint inhibitors e.g. the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor ipilimumab and the anti-PD-1/PD-L-1 antibodies nivolumab and pembrolizumab. Combined or sequential therapy involving targeted agents and immunotherapies is another area of considerable interest.
However, a significant proportion of patients with disease progression on BRAF inhibitor monotherapy have rapidly progressive disease and a very poor prognosis. These patients typically do not survive long enough to complete ipilimumab treatment and so fail to receive the full benefit of immunotherapy. 27, 28 However, the use of combined BRAF/MEK inhibition in the CoBRIM trial seems be associated with a lower occurrence of rapidly-progressing disease. This may provide more opportunity to complete subsequent immunotherapy treatments. Medical Oncology (ESMO) congress. Thirty patients were treated and the cohort that received vemurafenib plus cobimetinib run-in followed by the triple combination with atezolizumab, achieved a promising 83% ORR (10% complete response and 72% partial response) with a good safety profile. 31 The run-in phase with vemurafenib and cobimetinib in combination resulted very important due to the capability of the target therapy to recruit lymphocytes into the tumour, as demonstrated by the biopsies performed on tumour lesions before and after the treatment.
These lymphocytes are then activated with the adding of atezolizumab to the treatment, improving the efficacy of the therapy. A phase III trial (TRILOGY -NCT02908672) has been designed to assess the efficacy of this triple combination as front-line treatment of patients with BRAF-mutated metastatic melanoma.
Considering the efficacy data and the safety profile, combined BRAF and MEK inhibition is the new standard of care in patients with advanced BRAF-mutant melanoma. This is not an arrival point, but represent the base to build new combinations with other anti-melanoma agents, as anti PD-1/PDL1 checkpoint inhibitors, to improve always more the prognosis of BRAF-mutated metastatic melanoma patients.
